IVVD.US Invivyd Inc.

Healthcare Biotechnology USA Stocks
0.5821 USD
Close of Nov 15, 2026
0.5280 3.01
Market cap
USD 172M
P/E
-
P/B
0.95x
ROE
-94.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IVVD.US undervalued?

Graham number

The Graham number of Invivyd Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Invivyd Inc. fundamental analysis

No fundamental analysis for Invivyd Inc. yet.

Invivyd Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Invivyd Inc.

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibod…

Full company profile